Charles Schwab Investment Management Inc. Sells 8,477 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Charles Schwab Investment Management Inc. lessened its holdings in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 16.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,295 shares of the company’s stock after selling 8,477 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.17% of Contineum Therapeutics worth $829,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Johnson & Johnson bought a new position in Contineum Therapeutics in the 2nd quarter worth approximately $34,853,000. Perceptive Advisors LLC bought a new position in shares of Contineum Therapeutics in the second quarter worth $27,589,000. Versant Venture Management LLC purchased a new position in shares of Contineum Therapeutics in the second quarter valued at $16,169,000. Squarepoint Ops LLC bought a new stake in shares of Contineum Therapeutics during the 2nd quarter valued at $2,642,000. Finally, Driehaus Capital Management LLC bought a new position in Contineum Therapeutics in the 2nd quarter worth about $1,174,000.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Robert W. Baird assumed coverage on Contineum Therapeutics in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price target on the stock. Royal Bank of Canada reduced their target price on Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Baird R W upgraded Contineum Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $29.25.

Contineum Therapeutics Price Performance

CTNM opened at $13.75 on Thursday. The business’s fifty day simple moving average is $15.86 and its 200 day simple moving average is $17.71. Contineum Therapeutics, Inc. has a 52 week low of $12.33 and a 52 week high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last issued its earnings results on Wednesday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.01. As a group, analysts expect that Contineum Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Contineum Therapeutics Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).